IPHA
Innate Pharma S.A.
There isn't enough reported data to score IPHA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
IPHA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IPHA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IPHA PE Valuation
IPHA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IPHA Forward outlook
There aren't enough analyst estimates for IPHA to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IPHA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.61 | +$0.07 |
| Q2 2025 | -$0.61 | -$0.14 |
| Q4 2024 | -$0.68 | -$0.58 |
| Q2 2024 | -$0.47 | +$0.41 |
| Q4 2023 | -$0.10 | +$0.71 |
| Q2 2023 | -$0.88 | -$0.57 |
| Q4 2022 | -$0.81 | -$0.08 |
IPHA is still losing money, but less than at its worst: $0.61 per share over the past year, against $0.88 at its worst in mid-2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IPHA in the latest year-over-year earnings comparison.
IPHA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.5M | -35% |
| Q4 2025 | $4.6M | -47% |
| Q2 2025 | $5.4M | -61% |
| Q4 2024 | $8.6M | -64% |
| Q2 2024 | $13.7M | -69% |
| Q4 2023 | $23.8M | +77% |
| Q2 2023 | $44.7M | -12% |
| Q4 2022 | $13.4M | +34% |
IPHA's revenue has slid since its 2018 peak: $4M last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -692% | -479 points |
| Q4 2025 | -690% | -632 points |
| Q2 2025 | -523% | -522 points |
| Q4 2024 | -325% | +221 points |
| Q2 2024 | -213% | -232 points |
| Q4 2023 | -57% | +191 points |
| Q2 2023 | -1% | +161 points |
| Q4 2022 | -545% | -481 points |
IPHA's operating margin was −692% last quarter, down 479 points from the same quarter a year ago, near the bottom of its range since 2012.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IPHA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over IPHA on profitability, with a higher operating margin.
IPHA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$23.8M | +$10.9M |
| Q4 2025 | -$24.1M | -$12.9M |
| Q2 2025 | -$34.7M | -1234% |
| Q4 2024 | -$11.2M | +$12.3M |
| Q2 2024 | $3.1M | +$16.1M |
| Q4 2023 | -$23.5M | -$719.9K |
| Q2 2023 | -$13.1M | -1575% |
| Q4 2022 | -$22.8M | +$8.3M |
IPHA has burned cash in most quarters: −$94M over the past year, against −$56M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
IPHA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +4.2M shares |
| 1 year | +16% | +13M shares |
| 3 years | +19% | +14.9M shares |
| 5 years | +74% | +40M shares |
| Available history | +147% | +55.9M shares |
IPHA has 94M diluted shares, up 16% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
| Q2 2018 | — |
| Q4 2017 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over IPHA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IPHA Net Leverage
IPHA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IPHA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 8.2 | Oversold |
IPHA's weekly RSI is 42 (neutral) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IPHA PE vs Healthcare Sector
IPHA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IPHA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.53 | 2.6% below |
| 20 week MA | $1.77 | 16% below |
| 50 week MA | $1.71 | 13% below |
| 100 week MA | $1.85 | 19% below |
| 200 week MA | $2.23 | 33% below |
IPHA is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IPHA on trend strength, trading above more of its moving averages.
IPHA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.50 | $4.27 | -34% |
| 2021 | $4.27 | $5.17 | +21% |
| 2022 | $5.17 | $2.81 | -46% |
| 2023 | $2.81 | $2.80 | -0.4% |
| 2024 | $2.80 | $2.11 | -25% |
| 2025 | $2.11 | $1.75 | -17% |
| 2026 YTD | $1.75 | $1.49 | -15% |
IPHA has finished four years in a row lower, and it's down 15% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over IPHA on returns for 2026, with the stronger performance.